adUnits.push({
code: ‘Rpp_mundo_actualidad_Nota_Interna1’,
mediaTypes: {
banner: {
sizes: (navigator.userAgent.match(/iPhone|android|iPod/i)) ? [[300, 250], [320, 460], [320, 480], [320, 50], [300, 100], [320, 100]] : [[300, 250], [320, 460], [320, 480], [320, 50], [300, 100], [320, 100], [635, 90]]
}
},
bids: [{
bidder: ‘appnexus’,
params: {
placementId: ‘14149971’
}
},{
bidder: ‘rubicon’,
params: {
accountId: ‘19264’,
siteId: ‘314342’,
zoneId: ‘1604128’
}
},{
bidder: ‘amx’,
params: {
tagId: ‘MTUybWVkaWEuY29t’
}
},{
bidder: ‘oftmedia’,
params: {
placementId: navigator.userAgent.match(/iPhone|android|iPod/i) ? ‘22617692’: ‘22617693’
}
}]
});
U.S. lab Pfizer posted a net profit of $31.372 million in 2022, up 43% from a year earlier, driven largely by sales of its COVID-19 vaccine, according to information released this Tuesday.
Revenue rose 23% to a record $100.33 billion. If we subtract the proceeds from the sale of Kominarty, the trade name vaccine developed pfizer together with the German BioNTech and Paxlovid, an antiviral drug against more serious cases, the advance will be 2%.
By industry, the global biopharmaceutical division generated revenue of $98,988 million, up 24%, among which stand out $73,023 million contributed to primary health care, up 40%.
Record year for Pfizer
President and CEO pfizerAlbert Burla, stressed in a statement that 2022 was a record year for the company, not only in terms of revenue and earnings per share, which were the highest in its long history, but also, “more importantly”, in terms of the percentage of patients. positively evaluating pharmaceutical and the work they do.
In 2023 pfizer It expects its revenue to decline due to declining sales of COVID-19 vaccines and medicines and remain in the $67,000 million to $71,000 million range, representing a 33% to 29% drop from over $100,000. million dollars in 2022.
However, the head of the company believes in the potential pfizer continue to launch new products and develop others to ensure the continued and sustainable growth of the multinational corporation “throughout this decade and beyond.” (EFE)
Source: RPP
I’m a passionate and motivated journalist with a focus on world news. My experience spans across various media outlets, including Buna Times where I serve as an author. Over the years, I have become well-versed in researching and reporting on global topics, ranging from international politics to current events.